SJOGREN'S SYNDROME (SS)
Clinical trials for SJOGREN'S SYNDROME (SS) explained in plain language.
Never miss a new study
Get alerted when new SJOGREN'S SYNDROME (SS) trials appear
Sign up with your email to follow new studies for SJOGREN'S SYNDROME (SS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First human trial of mRNA injection for lupus and other autoimmune conditions begins
Disease control Recruiting nowThis early-phase study tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and side effects, not to cure the disease. Participants receive the drug by IV and are monitored closel…
Matched conditions: SJOGREN'S SYNDROME (SS)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 06:22 UTC
-
Revolutionary One-Shot CAR-T treatment targets lupus and more
Disease control Recruiting nowThis early-phase study tests a new therapy called TI-0032-III for people with severe autoimmune diseases like lupus that haven't responded to other treatments. The therapy uses a special injection to create cancer-fighting cells inside the body that target and destroy faulty immu…
Matched conditions: SJOGREN'S SYNDROME (SS)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated May 26, 2026 06:21 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these immune cells to see if it is safe and can help con…
Matched conditions: SJOGREN'S SYNDROME (SS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC